Eliquis® was first approved by the U.S. Food and Drug Administration in 2012. Eliquis® is a prescription medication designed to reduce the risk of blood clots and stroke in patients suffering from atrial fibrillation. Eliquis® was supposed to be more safe and effective than the traditional blood thinners like Coumadin® (also known as Warfarin), but Eliquis® (along with Pradaxa®) may put patients at risk for irreversible and life-threatening internal bleeding.
For more than 50 years doctors have prescribed Warfarin (marketed under the brand name Coumadin®) for patients who suffer from atrial fibrillation to reduce the risk of blood clots and strokes in these patients. Over the past decade, drug manufacturers have developed other drugs, like Eliquis®, to try and gain a market share of this industry. Like Pradaxa® and Xarelto®, Eliquis® belongs to a new family of anticoagulants that do not have a reversal agent, or antidote, to stop the drugs’ blood-thinning effects in the event of a serious bleed. Warfarin has an antidote that can be administered to a patient taking the drug if that patient develops a serious bleed, and the antidote immediately negates the blood-thinning effects of the drug. The severe bleed can then be treated and the patient’s blood will clot. Since Eliquis®, Pradaxa® and Xarelto® do not have an antidote, when a patient taking these drugs has a severe bleeding event, nothing can be done to make the blood clot to stop the bleed. This can result in serious injury or even death, particularly when the bleeding event occurs internally.
The attorneys at Franklin D. Azar and Associates are investigating the following Eliquis® side effects:
By filing a lawsuit, you may be able to recover compensation for any losses stemming from the bleeding event, such as: